The Comparison of Operative versus Medical Endocrine Therapy for Low-Risk DCIS (COMET) trial is currently ongoing and randomises low- and intermediate-grade ER-positive and HER2-negative DCIS to either standard management or active surveillance. Here, ERBB2 is linked to ductal breast carcinoma in situ.